Upload
darkgene
View
224
Download
0
Embed Size (px)
Citation preview
8/7/2019 probir project
1/55
INTRODUCTION
Drug design is the approach of finding new drugs , based on the biological targets (the
protein). Typically a drug target is a key molecule involved in a particular metabolic or signalling pathway that is specific to a disease condition or pathology, or to the
infectivity or survival of a microbial pathogen.
Rational Drug Design (RDD) is a process used in the biopharmaceutical industry to
discover and develop new drug compounds. RDD uses a variety of computational
methods to identify novel compounds, design compounds for selectivity, efficacy and
safety, and develop compounds into clinical trial candidates. These methods fall into
several natural categories structure-based drug design, ligand-based drug design, de
novo design and homology modeling depending on how much information is available
about drug targets and potential drug compounds.
In this project main emphasis is on Cyclooxygenase 2 which is an enzyme which is
present in human body and is responsible for inflamatory response of the immune system
of human body.The cyclooxygenase is naturally occuring enymes and produces
hormones called protaglandins.E.C number of cyclooxygenase is 1.14.99.1 .There aretwo isoforms of cyclooxygenase .Cyclooxygenase-1(Cox-1) & cyclooxygenase-2(Cox-
2). The genes for cox-1 and cox-2 are located on chromosomes 9 and 1. The human cox-
2 gene is 8.3 kilobases (kb) whereas the cox-1 gene is much larger 22 kb . In terms of
their molecular biology, COX-1 and COX-2 are of similar molecular weight (67 and 72
k Da respectively), and having 65% amino acid sequence homology and near-identical
catalytic sites.
Cox-1 Is a House Keeping Enzyme and Is Normally Present in a Variety of Area of the
Human Body Including Stomach.The cox-1 enzyme of the stomach produces certain
chemical messanger called prostaglandins that ensure the natural mucus lining which
protects the inner stomatch, mediate normal platelet function and regulate renal blood
flow.
11
http://en.wikipedia.org/wiki/Medicationhttp://en.wikipedia.org/wiki/Biological_targethttp://en.wikipedia.org/wiki/Moleculehttp://en.wikipedia.org/wiki/Metabolichttp://en.wikipedia.org/wiki/Pathwayhttp://en.wikipedia.org/wiki/Microorganismhttp://en.wikipedia.org/wiki/Pathogenhttp://en.wikipedia.org/wiki/Dalton_(unit)http://en.wikipedia.org/wiki/Medicationhttp://en.wikipedia.org/wiki/Biological_targethttp://en.wikipedia.org/wiki/Moleculehttp://en.wikipedia.org/wiki/Metabolichttp://en.wikipedia.org/wiki/Pathwayhttp://en.wikipedia.org/wiki/Microorganismhttp://en.wikipedia.org/wiki/Pathogenhttp://en.wikipedia.org/wiki/Dalton_(unit)8/7/2019 probir project
2/55
Cox 2 is 74 kD protein,Cox 2 contains 604 amino acids, it is located at chromosome
number 1,TATA box is present upstream of the start codon,it is usually absent in a cell
under normal condition and is expressed only in response to inflammatio,its over
expression in our system is a matter of concern as it may cause tumor formation.The
tumor formed may,under the influence of mitogens and other carcinogens, lead to cancer
formation.
There are many differences between cox 1 and cox 2.COX 1 is detectable under normal
conditions while COX 2 is not.COX 1 is located on chromosome number 9 while COX 2
is located on chromosome number 1 in human DNA.In COX 1 TATA Box is is ABSENT
while in COX 2 it is present.The lumen of COX 1 is thinner while that of COX 2 is
wider,so sometimes antibodies for COX 2 tend to affect COX 1 as well.The gene for COX 1 is longer as compare to COX 2. COX 1 is found in most mammalian cells while
COX 2 is abundant only in macrophages and other sites of inflammation.At position
523,in the gene,COX 1 has isoleucine while COX 2 has valine.
1.2 Pathways Of Formation And Action Of Cox-1 And Cox-2
22
8/7/2019 probir project
3/55
1.3 Production And Action Of Prostagladin
Arachidonic acid(a 20 carbon FA containing 4 double bonds) is liberated from the
membrane phospholipids by phospholipase A2, Which is activated by diverse stimuli.
Arachidonic acid is converted by cyclooxygenase to the unstable intermediate
prostaglandinH2 .
Prostaglandin H2 is converted by tissue specific isomerases to multiple prostaglandin
such as prostacyclin, thromboxane,prostaglandinD,E,F.
FIG. . The arachidonic acid cascade
33
8/7/2019 probir project
4/55
While initial studies upheld the concept that COX-2 is mainly an inflammatory, inducible
enzyme, more recent studies are beginning to reveal additional functions. We will now
turn our attention to the various organ systems and disease states where COX-2 appears
to have functional significance.
Prostaglandins are known to serve as important physiologic modulators of vascular tone
and sodium and water homeostasis in the mammalian kidney, including modulation of
glomerular hemodynamics, tubular reabsorption of sodium and water, and regulation of
renin secretion.
COX-2 seems to have some role in regulating brain function. PGs have long been knownas mediators of fever, of inflammatory reactions in neural tissue, and, more recently, of
brain function. The recognition that each of these processes involves induction of PG
synthesis has led to an appreciation of the role COX-2 plays in the PG-mediated
functions. In turn, COX-2 inhibition by an isoform-specific NSAID can effectively block
fever . Communication between local inflammatory sites and the brain endothelium is
mediated by cytokines such as IL-1, which can directly induce COX-2 expression in
these cells .
The use of NSAIDs causes a variety of problems in the gastrointestinal tract including
irritation and ulceration of the stomach lining . In animal studies, COX-2 is not induced
after exposure to radiation, and its presence is not essential for crypt cell survival . Under
these circumstances, COX-1 appears to play a major role, as it does in the stomach, in
maintaining proper glandular architectureIn addition, COX-2 is expressed during
inflammation and wound healing, and in animal models, treatment with COX-2 inhibitors
can exacerbate inflammation and inhibit healing. Nevertheless, COX-2 selective
inhibitors appear to be associated with less gastrointestinal damage than conventional
NSAIDs .
44
8/7/2019 probir project
5/55
Evidence provided by animal models of inflammatory arthritis strongly suggests that
increased expression of COX-2 is responsible for increased PG production seen in
inflamed joint tissues . COX-2 induction has been observed in both human osteoarthritis-
affected cartilage as well as in synovial tissue taken from patients afflicted with
The pro-inflammatory agents IL-1, TNF-, and LPS, as well as the growth factors TGF-,
EGF, PDGF, and FGF, have all been shown to induce COX-2 expression in this system.
On the other hand, the antiinflammatory cytokines IL-4 and IL-13, as well as the
immunosuppresive glucocorticoids, were shown to decrease COX-2 levels . Although the
synovial tissues of patients with osteoarthritis express lesser amounts of COX-2, primary
explant cultures of human osteoarthritis-affected cartilage spontaneously express large
amounts of COX-2 and PGs .The rapid expansion of knowledge about the role of COX-2in inflammation led to drug screens attempting to identify antiinflammatory agents
selective for COX-2 as well as to the rational design of highly selective COX-2
inhibitors.
COX-2 is induced in both local and central sites , and the question of whether COX-2
mediates pain reception or transmission is being investigated, primarily through the use
of COX-2 specific NSAIDs.. In fact, the COX-2 specific inhibitor Celecoxib was shown
in short-term human studies to effectively suppress the pain associated with dental work,
osteoarthritis, or rheumatoid arthritis without causing any significant gastroduodenal
lesions .
NSAID use reduces risk for Alzheimer's Disease (AD), with users of these agents having
as little as one half the risk of acquiring AD as those not taking NSAIDs. Several
population-based studies have detected a 4050% decrease in relative risk for colorectal
cancer in persons who regularly use aspirin and other NSAIDs .
55
8/7/2019 probir project
6/55
REVIEW OF LITERATURE
Barbara et-al , 2007 reported recently that changes in expression level of COX-2 are
correlated with development and progression of human melanoma. In this study, weinvestigated whether the COX-2 expression level might be a useful immunohistochemical
marker for distinguishing cutaneous melanomas from benign melanocytic lesions. Up to
now, immunohistochemical markers have not ensured satisfactory sensitivity and
specificity of differential pathologic diagnosis of melanoma. The expression of COX-2
was determined immunohistochemically in formalin-fixed, paraffin-embedded specimens
of 33 early Clark I/II melanomas and 58 naevi. Mean COX-2 expression in melanomas
was significantly stronger than in naevi (P[almost equal to]10-13). A simple diagnostic
algorithm using threshold values of the COX-2 expression level allows for differentiation
between early melanomas and naevi with high sensitivity (Se) and specificity (Sp) (for Se
between 91 and 100%, Sp values change between 96.5 and 51.7%). Areas under the
receiver operating characteristic curves were, respectively, 0.97+/-0.02 and 0.86+/-0.04
for the COX-2 expression in central and border regions of the lesions. For all the
melanomas (not only the early ones),the respective areas under the ROC curve values
were 0.98+/-0.01 and 0.97+/-0.02. In conclusion, COX-2 is the first
immunohistochemical marker that allows the distinguishing of early melanomas frombenign melanocytic lesions with both high sensitivity and specificity
Jeroen , et-al , 2005 worked on neuronal expression of cyclooxygenase-2 (COX-2) and
cell cycle proteins is suggested to contribute to neurodegeneration during Alzheimer's
disease (AD). The stimulus that induces COX-2 and cell cycle protein expression in AD
is still elusive. Activated glia cells are shown to secrete substances that can induce
expression of COX-2 and cell cycle proteins in vitro . Using post mortem brain tissue we
have investigated whether activation of microglia and astrocytes in AD brain can be
correlated with the expression of COX-2 and phosphorylated retinoblastoma protein
(ppRb). The highest levels of neuronal COX-2 and ppRb immunoreactivity are observed
in the first stages of AD pathology (Braak 0II, Braak A). No significant difference in
COX-2 or ppRb neuronal immunoreactivity is observed between Braak stage 0 and later
66
8/7/2019 probir project
7/55
Braak stages for neurofibrillary changes or amyloid plaques. The mean number of COX-
2 or ppRb immunoreactive neurons is significantly decreased in Braak stage C compared
to Braak stage A for amyloid deposits. Immunoreactivity for glial markers KP1, CR3/43
and GFAP appears in the later Braak stages and is significantly increased in Braak stage
V-VI compared to Braak stage 0 for neurofibrillary changes. In addition, a significant
negative correlation is observed between the presence of KP1, CR3/43 and GFAP
immunoreactivity and the presence of neuronal immunoreactivity for COX-2 and ppRb.
These data show that maximal COX-2 and ppRb immunoreactivity in neurons occurs
during early Braak stages prior to the maximal activation of astrocytes and microglia. In
contrast to in vitro studies, post mortem data do not support a causal relation between the
activation of microglia and astrocytes and the expression of neuronal COX-2 and ppRb in
the pathological cascade of AD
Anna , et-al , 2007 work showed that Cyclooxygenase-2 (COX-2) is the inducible form of
the enzyme involved in the first steps of the prostaglandins and thromboxane synthesis.
COX-2 up-regulation is demonstrated in tumors where it can modulate tumoral
progression, metastasis, multidrug resistance, and angiogenesis. Experimental data
suggest a possible therapeutic use of the COX-inhibitors nonsteroidal antiinflammatory
drugs (NSAIDs). NSAIDs can block tumor growth through many mechanisms, especially
through antiangiogenic and proapoptotic effects. Moreover, NSAIDs can also improve
the efficacy of radiotherapy, chemotherapy, and hormonal therapy. This study reviews
the COX-2 expression as evaluated through immunohistochemistry and real time
polymerase chain reaction (RT-PCR) in 23 meningiomas [14 World Health Organization
(WHO) grade I; 5 WHO grade II; 3 WHO grade III; 1 oncocytic meningioma]. At
immunohistochemistry all the lesions but 4 (83%) were COX-2 positive. At RT-PCR 9
meningiomas, 8 WHO grade I and 1 WHO grade II, showed a COX-2 expression greater
than the reference value (average expression of all meningiomas that we studied). Theassociation between tumor grade and immunohistochemical or RT-PCR COX-2
expression was not significant (P=0.427 and P=0.251, respectively). In conclusion, even
if further studies on larger series are necessary, the common COX-2 overexpression in
meningiomas may suggest considering the COX-2 inhibitors, alone or in combination
77
8/7/2019 probir project
8/55
with radiotherapy, a potential area of therapeutic intervention in some selected
meningiomas.
Marco , et-al, 2005 work showed that Cyclooxygenase 2 (COX-2) is an inflammation-
associated enzyme involved in the pathogenesis of many solid tumors, but little is known
about its presence and role in hematologic neoplasms. Multiple myeloma (MM) is known
to involve a deregulated cytokine network with secretion of inflammatory mediators. We
thus decided to investigate the involvement of COX-2 in this neoplasm. Western blotting
(WB) was used to evaluate 142 bone marrow (BM) specimens, including MM and
monoclonal gammopathy of undetermined significance (MGUS). Selected cases under-
went further evaluation by WB on purified CD138 + cells, immunohistochemistry (IC),
and real-time
polymerase chain reaction (PCR) for mRNA expression. COX-2 wasexpressed in 11% (2 of 18) of MGUS specimens, 31% (29 of 94) of MM at diagnosis, and
47% (14 of 30) of MM with relapsed/refractory disease. COX-2 positivity was associated
with a poor outcome in terms of progression-free (18 vs 36 months; P < .001) and overall
survival (28 vs 52 months; P < .05). Real-time PCR showed COX-2 mRNA
overexpression. IC and cell separation studies demonstrated COX-2 expression to be
restricted to malignant plasma cells. This is the first report of the presence and prognostic
role of COX-2 expression in MM. Future studies will assess COX-2 involvement in other
hematologic tumors and its potential use as a therapeutic or chemo-preventive target in
onco-hematology.
Phuong, et-al, 2002 Their studies were performed to ascertain the relative abundance of
E prostaglandin (EP) receptor mRNAs in tissues that are major targets, or major
degradative sites, of insulin; to identify which EP receptor type mediates PGE 2 inhibition
of insulin secretion in pancreatic islets; and to examine possible sites of action through
which sodium salicylate might affect IL-1/PGE 2 interactions. Real-time fluorescence-
based RT-PCR indicated that EP3 is the most abundant EP receptor type in islets, liver,
kidney, and epididymal fat. EP3 mRNA is the least, whereas EP2 mRNA is the most,
abundant type in skeletal muscle. Misoprostol, an EP3 agonist, inhibited glucose-induced
insulin secretion from islets, an event that was prevented by preincubation with pertussis
toxin, by decreasing cAMP. Electromobility shift assays demonstrated that sodium
88
8/7/2019 probir project
9/55
8/7/2019 probir project
10/55
recurrent neoplastic polyps of the large bowel in patients with a history of colorectal
adenomas.A total of 2586 patients with a history of colorectal adenomas underwent
randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to
receive placebo. All investigator-reported serious adverse events that represented
potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an
external committee. A total of 46 patients in the rofecoxib group had a confirmed
thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-
years), as compared with 26 patients in the placebo group during 3327 patient-years of
follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95
percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became
apparent after 18 months of treatment; during the first 18 months, the event rates were
similar in the two groups. The results primarily reflect a greater number of myocardialinfarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier
separation (at approximately five months) between groups in the incidence of
nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or
cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo
group,4.61;95percent confidence interval, 1.50 to 18.83). Overall and cardiovascular
mortality was similar in the two groups. CONCLUSIONS: Among patients with a history
of colorectal adenomas, the use of rofecoxib was associated with an increased
cardiovascular risk
Jana, et-al , 2002 worked on Dexamethasone and concluded that it is very effective for
controlling peritumoral cerebral edema, it is associated with distressing side effects that
decrease the quality of life for many patients. One potential mechanism to explain the
ability of dexamethasone to repair blood-brain barrier dysfunction is through the
inhibition of cyclooxygenase-2 (COX-2). The purpose of this study was to determine in a
rat brain tumor model whether SC-236, a selective COX-2 inhibitor, is as effective asdexamethasone. Twenty-nine adult male Fischer 344 rats were implanted with
intracerebral 9L gliosarcomas and divided into 3 treatment groups. One group ( n = 9)
served as controls, another ( n = 9) was treated with dexamethasone (3 mg/kg p.o. daily),
and a third group ( n = 11) received SC-236 (3 mg/kg p.o. daily). A survival study was
101
8/7/2019 probir project
11/55
performed. The median survival in the control group was 16 days, compared with 23 days
for the dexamethasone group and 23 days for the COX-2 inhibitor group. Kaplan-Meier
analysis on pairwise group comparisons showed improved survival that was statistically
significant for each treatment group compared with the control group (log-rank test P =
0.009 for dexamethasone to control and P = 0.005 for COX-2 to control), and no
significant difference in survival for the COX-2 compared with dexamethasone (log-rank
test P = 0.2). These results suggest that a selective COX-2 inhibitor appears to be as
effective as dexamethasone in prolonging survival in a rat brain tumor model
Lisa, et-al , 2002 indicated that prostanoids, such as prostaglandins, play a regulatory role
in several forms of neural plasticity, including long-term potentiation, a cellular model for
certain
forms of learning and memory. In these experiments, the significance
of the COXisoforms cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in post-training
memory processes was assessed. Adult male Long-Evans rats underwent an eight-trial
(30-sec intertrial interval) training session on a hippocampus-dependent (hidden platform)
or dorsal striatal-dependent (visible platform) tasks in a water maze. After the
completionoftraining, rats received an intraperitoneal injection of the nonselective COX
inhibitor indomethacin, the COX-1-specific inhibitor piroxicam, the COX-2-specific
inhibitor N -[2-cyclohexyloxy-4-nitrophenyl]-methanesulfonamide (NS-398), vehicle
(45% 2-hydroxypropyl- -cyclodextrin in distilled water), or saline. On a two-trial
retention test session 24 h later, latency to mount the escape platform was used as a
measure of memory. In the hidden platform task, the retention test escape latencies of rats
administered indomethacin (5 and 10 mg/kg) or NS-398 (2 and 5 mg/kg) were
significantly higher than those of vehicle-treated rats, indicating an impairment in
retention. Injections of indomethacin or NS-398 that were delayed 2 h post-training had
no effect on retention. Post-training indomethacin or NS-398 had no influence on
retention of the visible platform version of the water maze at any of the dosesadministered. Furthermore, selective inhibition of COX-1 via post-training piroxicam
administration had no effect on retention of either task. These findings indicate that COX-
2 is a required biochemical component mediating the consolidation of hippocampal-
dependent memory
111
8/7/2019 probir project
12/55
MATERIALS AND METHODS
3.1. Retrieval of Protein Sequence of Cox 2 in Homo sapiens:
Protein sequence of cox 2 in Homo sapiens was done from National Center Of Biotechnology information( www.ncbi.nlm.nih.gov/). The sequence of protein was in
fasta formet.
3.2 Homology Modelling :
Homology modelling is required when the exact structure of the protein is not
available.The structure of cyclooxygenase 2 was also unavailable,so homology modeling
was required.It is also known as comperative modelling.Here we model themolecule(protein) from amino acid sequence by following a protocol to model.The amino
acid sequence is query or target sequence.Homo;ogy modeling techniques depend on
identificatiction of one or more stuctures known as template,which resembles the
sructure of query sequence.The sequence alignment and template stucture are used to
produce a structural model of the target.Usually sequence similarity corresponds to high
structural similarity.
Different softwares are used for Homology Modelling such as SWISS MODEL
SERVER.,CPH MODEL SERVER.,MODELLER etc. In this project Swiss Model server
is used for Homology Modelling.The methodology for homology modeling with swiss
Model Server is:
3.2.1. BLAST
BLAST (Basic Local Alignment Search Tool),( www.ncbi.nlm.nih.gov/BLAST)is a tool by
which we can find alignment between our query in form of nucleotide or protein
sequence,against the database of BLAST.The results show us the extent to which our
query sequence matches the sequences stored in the BLAST database.In case our
sequence is a novel entry,it does not show any results.Here I carried out protein-protein
121
http://www.ncbi.nlm.nih.gov/BLAST)ishttp://www.ncbi.nlm.nih.gov/BLAST)is8/7/2019 probir project
13/55
BLAST of my query sequence,against pdb(protein data bank);which consists of amino
acid sequences of the proteins submitted in pdb .The results generated by BLAT were
furthur used for the modeling of the protein. After we get BLAST results we carry out
CLUSTAL W.
3.2.2. CLUSTAL W
CLUSTAL-W (www.ebi.ac.uk/clustalw/) is a multiple sequence alignment programme
for DNA or proteins.It provides multiple sequence alignment forgiven sequence.It gives
the match between the query sequences and allows us to have the idea of best match
between our target sequence and template.This informationis furthur used in swiss
model.Evolutionary relationships can be viewed by cladograms or phylograms.
3.2.3. Swiss Model:
It is totally automated protein structure homology modeling server ,accessible via
ExPASy web server or from swiss pdb viewer.(www.swissmodel.expasy.org//SWISS-
MODEL.html).
SWISS MODEL SERVER: It is used for final modeling of protein,using results of
CLUSTAL-W.Basically there are three moes os SWISS MODEL,which are:
1. First approach mode:it only requires a single amino acid sequence information as input
data.The server automatically selects suitable template.However the user may specify
upto five template structures either from ExPDB library,or opload co-ordinate files.The
process starts if atleast one template sequence has a identity of more than 25% with
submitted target sequence.The reliability of model decreases as sequence identity
decreases.
2. Alignment Mode:it is done by submitting a sequence alignment.The ser predicts the
target sequence and the one ,which is structurally known protein FROM ExPDB
library.The server builds yhe model according to given alignment.
131
8/7/2019 probir project
14/55
3. Project Mode:here user submits a manually optimized modeling request to SWISS
MODEL server The starting moe is a Deep View project file.It contains superposed
template structures and alignment between target and template.It allows template
selection or gap placement in the alignment.It can also be used to improve the output of
first approach mode.
Here alignment mode of SWISS MODEL was used to predict structure of cox 2 model.
There are certain steps to be followed in this process,which are:
Retrieval of protein seuence from NCBI in FASTA format.
Protein BLAST of protein sequence obyained in last step against pdb(protein databank).
Selecting the second,third,fourth match results and obtaining their FASTA format of
sequence.
Puting the results obtained in last step alongwith target protein sequence of protein
in a notepad.The sequences obtained in last steo are pot\entail te,plates.
Open CLUSTAL W page and paste the sequence obtained in last step in window
displayed and submit.
Open SWISS MODEL SERVER page and paste the sequence in window and
submit.
The results are obtained,asve the result file with (.pdb) extension,to save a pdb file.
Open the saved file with rasmol viewer to view 3-D image of the modeled protein.
141
8/7/2019 probir project
15/55
3.3 Retrieval of inhibitor against Cox-2:
Inhibitor against Cox-2 protein retrieved through two major sources.
1. BRENDA (www.brenda.uni-koeln.de) is the main collection of enzyme functionaldata available to the scientific community.BRENDA is maintained and developed at the
institute of Biochemistry at the University of Cologne
2. NCBI Pubchem Compound : PubChem Structure Search allows PubChem
Compound Database to be queried using a chemical structure. Chemical structure queries
may be sketched using the PubChem Sketcher. You may also specify the structural query
input by PubChem Compound Identifier (CID), SMILES, SMARTS, InChI, Molecular
Formula, or by upload of a supported structure file format.
This standardizing allows NCBI to compute chemical parameters and similarity
relationships between compounds. The compounds are grouped into levels of chemical
similarity from most general to most specific: same bonding connectivity and any
tautomer; same bonding connectivity; same stereochemistry; same isotopes; and same
stereochemistry and isotopes. PubChem Compound also indexes these chemicals using
34 fields, many of which represent computed chemical properties such as the number of
chiral centers, the number of hydrogen bond donors/acceptors, molecular formula and
weight, total formal charge, and octanol-water partition coefficients (XlogP). These
groups are provided as Entrez links that allow similar compounds to be retrieved quickly
3.3 Building of 3d structure (PDB file) of Inhibitors:
2D structure of potent inhibitors are obtained by submitting the CID no to the NCBIs
Pubchem compound and convert it into SDF format then convert it into PDB format to
get the 3D-structure.
Procedure of converting 2D-structure into 3D-structure
1) To select SDF format from NCBI.
151
8/7/2019 probir project
16/55
Open google and enter NCBI home page.
Choose pubchem compound from search drop-down menu.
Type CID no.
When answers come ,Change display format to SDFand save it
161
8/7/2019 probir project
17/55
8/7/2019 probir project
18/55
3.5 Docking Of Flexible Ligands to the Receptors
For docking the flexible ligands to the receptors following softwares can be used whichare listed below :
SN Name License Term Platform Keyword1 Autodock Commercial UNIX,LINUX,SGI GA/LGA,MC2 Affinity Commercial SGI Monte Carlo
method3 Dock Vision Commercial LINUX.IRIS MC,GA4 DOT(Daughter
of Turnip)
Free Supercomputers,UNIX
5 Flex X Commercial UNIX Fragnent Based6 Shape E-mail request UNIX Structure and
chemistry of
molecular
surface7 LEAPFROG Commercial SGI ligand design8 Q site Commercial UNIX,LINUX,SGI Mixed
quantum and
molecular
mechanics9 HINT Commercial Windows
2000,SGI,LINUX
Hydropathic
interaction10 GOLD Free evaluation UNIX GA
3.3.2 Cygwin : It is a collection of free software tools originally developed from
Cygnus solutionsto allow various versions of Microsoft windows to act similarto a
Linux operating system.As Autodock is programmed to run on Linux operating system,so
181
8/7/2019 probir project
19/55
for those systems which run on windows,cygwin is a must.It can be freely downloaded
from the internet.
3.3.3. AUTODOCK: Autodock is a suite of automated docking tools. It is designed to
predict how small molecules, such as substrates or drug candidates, bind to a receptor of
known 3D structure. AutoDock actually consists of two main programs: AutoDock
performs the docking of the ligand to a set of grids describing the target protein; Auto
Grid pre-calculates these grids. In additions to using them for docking, the atomic affinity
grids can be visualized. This can help, for example, to guide organic synthetic chemists
design better binders .
1.Autogrid.
2.Autodock.
3.3.3.1 . AUTOGRID :
A.Peparing a Ligand for Autodock :
i.In autodock page,go to ligand and in it click on input.
ii.In input click on open AD3.
iii.Go to your folder and open the (.pdb) file of the inhibitor.
iv.Go to Ligand again in autodock window and in it Torsion Tree and click ondetect
route.
v.In Ligand select Torsion Tree and click on Choose Torsionand click on done.
vi.Go to Ligand again and select Torsion Tree and select Set number Of
Torsions.The number of torsions
vii.Set number of torsions less than or equal to 6 and click on Dismiss.
191
8/7/2019 probir project
20/55
viii.Go to Logand and in it to Output and then click on Save As PDBQ.Then go to
your folder a save your this file as (inhibitor name.out.pdbq).
B. Preparing A Macromolecule For Autodock:
i.Go to Grid and in it click on Macromolecule and in it click on Open AG3.
ii.Open the (.pdb) file from your folder and click on OK.
iii.Now save this file as protein name.pdbqs.
iv.Come back to autodock window and press shift key+n to visualize the protein on
screen.
C.Preparing The Grid Parameter File:
i.Go to Grid and select Set Map Types and in it select Choose Ligand AG3.
ii.Now select the inhibitor file.
iii.Now click on Ligand and then click on Accept.
iv.Go to Grid and selectGrid Box.
v.On the window that opens,set x,y,z co-ordinate axes so that the macromolecule is
completely covered.You can rotate the molecule by pressing shift+right click of mouse.
vi.On the same window,click on File and there click on Saving Current Setting.
vii.Go to Grid again and in it go to Output,then click on SaveGPF(AG3)
viii.Save this file in your folder as protein name.gpf.
202
8/7/2019 probir project
21/55
ix.Go to Grid and in it go to Edit Grid and clik it,then click on Accept.
x.Go to your folder and copy the path of your folder eg(C:\probir) and open the (.gpf) file
in your folder wit wordpad and paste this path followed by \ on left of wherever you
find protein name in this file.It is to be noted that there should not be any gap between
path and protein name.
xi.Click on Save in this window after you finish.
3.3.3.2.AUTODOCK :
A.Startimg Autodogrid:
i.Go to Run and in it click on Run Autogrid.
ii.On the window that opens on the first Browse option click and select autogrid.exe
file.
iii.Then in second Browse option click and go to your folder and open the (.gpf) file.
iv.Back to autogrid, select the entire bottom line(i.e. the path) of the Browse window
and press cntrl+c.
v.Open Cygwin and in it go to Edit and Paste the path copied and press Enter.
B.Preparing A docking Parameter For Autodock:
i.Click on Docking on the the autodock window.
ii.In it select on Macromolecule and in it click on Choose AD3.
iii.Select your protein in the window that opens and click on OK.
212
8/7/2019 probir project
22/55
iv.Click on Select Macromolecule and click on window that opens twice.
v.Go to Docking and in it go to Ligand and in it click on Choose (AD3).
vi.On the window that opens click and select the ligand.
vii.Click on Select Ligand and click on Accept on the window.
viii.Go to docking again and selectSearch Parameterand in it click on Genetic
Algorithm.Click Accept on yhe window that opens.
ix.Go to Docking again and in it click on Docking Parameters.Click on Accept on
the window that opens.
x.Go to Docking again and in it select Output and in it click on Lamarkian
GA(AD3).Then go to your folder and save the file as (inhibitor name.dpf).
xi.Go to your folder and copy the path of (.dpf) file.
xi.Open this (.dpf) file in wordpad and paste the copied path everywhere you find
inhibitor name,followed by \ i.e.path+\,on left of the inhibitor name.Continue till you
reach on yhe line with move and here do the same.
xii.Save the page.
C.Starting Autodock:
i.Back to autodock,click on Run and in it click on Run Autodock.
ii.On the window that opens on first Browse option,click it and open the autodock.exe
file.
iii.On the second Browse option,click and go to your folder and open the the (.dpf) file.
iv.Come back to Browse window and copy the path at the bottom by selecting it and
then pressing cntrl+c.
222
8/7/2019 probir project
23/55
v.Open Cygwin and go to Edit and click on Paste .
vi.Press Enter to run Autodock.
D.Analysing Autodock Results:
i.Click on Analyse on the autodock window and in it click on Docking.
ii.Go to your folder and open the (.dlg) file. And click ok.
iii.Now go to Macromolecule in Analyse and go to your folder and open the (.pdbqs)
file of the target.
iv.Press Shift+n to visualize the macromolecule on the screen.
v.Go to Conformation in Analyse and in it click on Load,a box appears.
vi.Go to Conformation again and click on Play,another window opens.
vii.In the Play window,click on (&) sign ,a new window opens.
viii.Now on the first window that came on pressing Load go to its second line and click
it.It shows the docking energy and various other docking parameters.Note it.The more
negative dock energy,the better inhibitor is;positive dock energies(if found) are neglected
as it is not a proper result.
ix.Now go to the window which came in Play,in it click on the direction buttons to
analyse each of the ten active sites.It gives information about various parameters on a
particular active site.Here we also search for hydrogen bonds which are shown on the
bottom of that window and we can also find the amino acid to which the ligand binds.
232
8/7/2019 probir project
24/55
x.Expand the bottom of the box which we got on clicking Load.
xi.Click on Write Current Coords and go to your folder and save this file as
(inhibitor.docked.pdbq).
xii.Record the results.
3.4. PMV (Python Molecular Viewer):
Python Molecular Viewer is a tool to view the binding of hydrogen bonds in the target
molecule.It helps to visualise and analyse the hudrogen bonds.The process of operation of PMV is enlisted below:
Procedure For Operation Of PMV:
i.Open PMV.
ii.Go to File and click on Browse Command.
iii.In the window that opens,click on pmv
.
iv.In the adjacent window click on trace command,then click on Load.Again in the
adjacent window of pmv click on hbond command and load this too.
v.Go to file in PMV and click on Read Molecule nad go to your folder and open
(protein name.pdbqs) file.
vi.Go to Compute and in it go to Trace.
vii.Here click on Compute Extrude Trace.
242
8/7/2019 probir project
25/55
8/7/2019 probir project
26/55
xxiii.Click ok.
xxiv.Go to File and in it go to Read Molecule.
xxv.By last step go to your folder and open the (inhibitor.docked.pdbq) file and open it.
xxvi.Go to Select and in it click on Direct Select.
xxvii.In the window that opens click on Molecule and in it click on your
macromolecule.
xxviii.Click on Molecule again and now click on the ligand or the inhibitor.
xxix.Click on Dismiss.
xxx.Go to Display.
xxxi.In it click on Stick and Balls.
xxxii.In the window that opens set Stick Quality to 15 and set Ball Quality to 15.
xxxiii.Click ok.
xxxiv.Go to Color and click on By Atom Type.
xxxv.In the next window click on Stick and Balls.
xxxvi.Click ok.
xxxvii.Go to Hydrogen Bond.
262
8/7/2019 probir project
27/55
xxxvii.In it go to Build.
xxxviii.In it click on Set Parms+Build.
xxxix.In the window that opens click on specify two sets.
xxxx.In the next window click on,in the top list under Molecule List click it and select
macromolecule.
xxxxi.I the bottom Molecule List,click it and select the ligand.
xxxxii.Click ok.
xxxxiii.Go to H bond and in it click on Display.
xxxxiv.In it click on as lines.
xxxxv.Click Dismiss in the window that opens.
xxxxvi.Again go to Display and click on Cylinders.
xxxxvii.In the window that opens adjust bond length and bond radius of the hydrogen
bond by using mouse,to a suitable size.
xxxxviii.Go to Dj vu GUI and click on camera in the lower window.
xxxxix.On the window which lengthens, click on Set Background Color.
xxxxx. Click on SW and then click on S.
xxxxxi.Go to File of PMV and click on save as.
272
8/7/2019 probir project
28/55
8/7/2019 probir project
29/55
RESULTS AND DISCUSSION
Retrieval of protein sequence of COX2 (cyclooxygenase2).
>gi|3915797|sp|P35354|PGH2_HUMAN Prostaglandin G/H synthase 2 precursor(Cyclooxygenase-2) (COX-2) (Prostaglandin-endoperoxide synthase 2)(Prostaglandin H2 synthase 2) (PGH synthase 2) (PGHS-2) (PHS II)
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPT
PNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPP
VPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGL
GHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGL
VPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPE
LLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELY
PALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKG
CPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKERSTEL
292
8/7/2019 probir project
30/55
BLAST Result:-
Fig4.1: BLAST RESULT
4.2.ClustalW Results:
303
8/7/2019 probir project
31/55
Results of searchNumber of sequences 4Alignment score 20349Sequence format PearsonSequence type aaClustalW version 1.83JalView Output file clustalw-20070718-12352061.outputAlignment file clustalw-20070718-12352061.alnGuide tree file clustalw-20070718-12352061.dndYour input file clustalw-20070718-12352061.input
.
Scores Table
SeqA Name Len(aa) SeqB Name Len(aa) Score
1 seq1 604 2 seq2 587 861 seq1 604 3 seq3 552 88
1 seq1 604 4 seq4 552 87
2 seq2 587 3 seq3 552 99
2 seq2 587 4 seq4 552 99
3 seq3 552 4 seq4 552 99
CLUSTAL W (1.83) multiple sequence alignment
seq2 -----------------ANPCCSNPCQNRGECMSTGFDQYKCDCTRTGFYGENCTTPEFL 43
seq4 -----------------ANPCCSNPCQNRGECMSTGFDQYKCDCTRTGFYGENCTTPEFL 43
seq3 -----------------ANPCCSNPCQNRGECMSTGFDQYKCDCTRTGFYGENCTTPEFL 43
seq1 MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL 60
seq2 TRIKLLLKPTPNTVHYILTHFKGVWNIVNNIPFLRSLIMKYVLTSRSYLIDSPPTYNVHY 103
seq4 TRIKLLLKPTPNTVHYILTHFKGVWNIVNNIPFLRSLIMKYVLTSRSYLIDSPPTYNVHY 103
seq3 TRIKLLLKPTPNTVHYILTHFKGVWNIVNNIPFLRSLIMKYVLTSRSYLIDSPPTYNVHY 103
seq1 TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY 120
seq2 GYKSWEAFSNLSYYTRALPPVADDCPTPMGVKGNKELPDSKEVLEKVLLRREFIPDPQGS 163
seq4 GYKSWEAFSNLSYYTRALPPVADDCPTPMGVKGNKELPDSKEVLEKVLLRREFIPDPQGS 163
313
http://www.ebi.ac.uk/jalview2/http://www.ebi.ac.uk/cgi-bin/jobresults/clustalw/clustalw-20070718-12352061.outputhttp://www.ebi.ac.uk/cgi-bin/jobresults/clustalw/clustalw-20070718-12352061.alnhttp://www.ebi.ac.uk/cgi-bin/jobresults/clustalw/clustalw-20070718-12352061.dndhttp://www.ebi.ac.uk/cgi-bin/jobresults/clustalw/clustalw-20070718-12352061.inputhttp://www.ebi.ac.uk/jalview2/http://www.ebi.ac.uk/cgi-bin/jobresults/clustalw/clustalw-20070718-12352061.outputhttp://www.ebi.ac.uk/cgi-bin/jobresults/clustalw/clustalw-20070718-12352061.alnhttp://www.ebi.ac.uk/cgi-bin/jobresults/clustalw/clustalw-20070718-12352061.dndhttp://www.ebi.ac.uk/cgi-bin/jobresults/clustalw/clustalw-20070718-12352061.input8/7/2019 probir project
32/55
seq3 GYKSWEAFSNLSYYTRALPPVADDCPTPMGVKGNKELPDSKEVLEKVLLRREFIPDPQGS 163
seq1 GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVGKLLLRRKFIPDPQGS 180
seq2 NMMFAFFAQHFTHQFFKTDHKRGPGFTRGLGHGVDLNHIYGETLDRQHKLRLFKDGKLKY 223
seq4 NMMFAFFAQHFTAQFFKTDHKRGPGFTRGLGHGVDLNHIYGETLDRQHKLRLFKDGKLKY 223
seq3 NMMFAFFAQHFTHQFFKTDHKRGPGFTRGLGHGVDLNHIYGETLDRQHKLRLFKDGKLKY 223
seq1 NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY 240
seq2 QVIGGEVYPPTVKDTQVEMIYPPHIPENLQFAVGQEVFGLVPGLMMYATIWLREHQRVCD 283
seq4 QVIGGEVYPPTVKDTQVEMIYPPHIPENLQFAVGQEVFGLVPGLMMYATIWLREHQRVCD 283
seq3 QVIGGEVYPPTVKDTQVEMIYPPHIPENLQFAVGQEVFGLVPGLMMYATIWLREHNRVCD 283
seq1 QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD 300
seq2 ILKQEHPEWGDEQLFQTSKLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNQQFQYQ 343
seq4 ILKQEHPEWGDEQLFQTSKLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNQQFQYQ 343seq3 ILKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNQQFQYQ 343
seq1 VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ 360
seq2 NRIASEFNTLYHWHPLLPDTFNIEDQEYSFKQFLYNNSILLEHGLTQFVESFTRQIAGRV 403
seq4 NRIASEFNTLYHWHPLLPDTFNIEDQEYSFKQFLYNNSILLEHGLTQFVESFTRQIAGRV 403
seq3 NRIASEFNTLYHWHPLLPDTFNIEDQEYSFKQFLYNNSILLEHGLTQFVESFTRQIAGRV 403
seq1 NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV 420
seq2 AGGRNVPIAVQAVAKASIDQSREMKYQSLNEYRKRFSLKPYTSFEELTGEKEMAAELKAL 463
seq4 AGGRNVPIAVQAVAKASIDQSREMKYQSLNEYRKRFSLKPYTSFEELTGEKEMAAELKAL 463seq3 AGGRNVPIAVQAVAKASIDQSREMKYQSLNEYRKRFSLKPYTSFEELTGEKEMAAELKAL 463
seq1 AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL 480
seq2 YSDIDVMELYPALLVEKPRPDAIFGETMVELGAPFSLKGLMGNPICSPQYWKPSTFGGEV 523
seq4 YSDIDVMELYPALLVEKPRPDAIFGETMVELGAPFSLKGLMGNPICSPQYWKPSTFGGEV 523
seq3 YSDIDVMELYPALLVEKPRPDAIFGETMVELGAPFSLKGLMGNPICSPQYWKPSTFGGEV 523
seq1 YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV 540
seq2 GFKIINTASIQSLICNNVKGCPFTSFNVQDPQPTKTATINASASHSRLDDINPTVLIKRR 583
seq4 GFKIINTASIQSLICNNVKGCPFTSFNVQ------------------------------- 552
seq3 GFKIINTASIQSLICNNVKGCPFTSFNVQ------------------------------- 552
seq1 GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER 600
seq2 STEL 587
seq4 ----
seq3 ----
323
8/7/2019 probir project
33/55
seq1 STEL 604
4.3 SWISS MODEL Result: _________________
4.4. INHIBITOR TABLE:
Table 4.1 : List of inhibitors against COX2(cyclooxygenase2).
Inhibitor
Name
Structure IUPAC Name IC50
Value
Side
effects
Clinical
phase
Sodium
Parecoxib
sodium N-[4-(5-
methyl-3-phenyl-1,2-
oxazol-4-
yl)phenyl]sulfon
ylpropanimidate
0.005
+/-0.1
micro
moles
/L
Gastro
-
intesti
nal
infecti
on
Phase IV
celecoxib 4-[5-(4-methylphenyl)-
3-
(trifluoromethyl)pyrazol-1-
yl]benzenesulfon
amide
4.8
+/-0.4
nmol/
L
Gastro
intesti
nal
infecti
on,ulc
ers
Phase III
Valdecoxi
b
4-(5-methyl-3-
phenyl-1,2-
oxazol-4-
yl)benzenesulfon
amide
0.001
+/-
0.3mi
croM
Hyper
algesia
:increa
sed
sensitivity to
pain
Phase III
333
http://%20void%20window.open%28%27../image/structurefly.cgi?cid=119607&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)8/7/2019 probir project
34/55
Rofecoxib 4-(4-methylsulfonylp
henyl)-3-phenyl-
5H-furan-2-one
(4.7+/
-0.5)
nmol/
L
headac
he,ble
eding
Phase III
Doxorubic
in
(7S,9R)-7-
[(2S,4S,5S,6S)-
4-amino-5-
hydroxy-6-
methyl-oxan-2-
yl]oxy-6,9,11-trihydroxy-9-(2-
hydroxyacetyl)-
4-methoxy-8,10-
dihydro-7H-
tetracene-5,12-
dione
0.42+/
-0.3
micro
M
Hair
loss,fa
tigue
Phase II
Etoricoxib 5-chloro-2-(6-methylpyridin-3-
yl)-3-(4-methylsulfonylp
henyl)pyridine
1.1+/-
0.1
micro
M
Fatigu
e and
dizines
s
Phase III
Lumiracox
ib
2-[2-[(2-chloro-
6-fluoro-
phenyl)amino]-
5-methyl-
phenyl]acetic
acid
0.06+/
-0.3
micro
M
dizzine
ss or
sleepin
ess
Phase III
343
http://%20void%20window.open%28%27../image/structurefly.cgi?cid=151166&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)http://%20void%20window.open%28%27../image/structurefly.cgi?cid=123619&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)http://%20void%20window.open%28%27../image/structurefly.cgi?cid=31703&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)http://%20void%20window.open%28%27../image/structurefly.cgi?cid=5090&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)8/7/2019 probir project
35/55
Nimesulid
e
N-(4-nitro-2-
phenoxy-
phenyl)methanes
ulfonamide
0.071
+/-0.5
micro
M
Liver
enlarg
ement,
liver
toxific
ation
Phase III
Dipyrone sodium [(1,5-dimethyl-3-oxo-
2-phenyl-
pyrazol-4-yl)-
methyl-
amino]methanes
ulfonate
4.6+/-
0.3
micro
M
agranulo
cytosis
Phase II
Thalidomi
de
2-(2,6-dioxo-3-
piperidyl)isoindo
le-1,3-dione
3.1+/-
0.3
micro
M
constipa
tion,
dizzines
s
Phase III
Etodolac 1,8-diethyl-1,3,4,9-
tetrahydropyrano
-[3,4-b]indole-1-
acetic acid.
2.9+/-
0.4
micro
M
allergi
c
reactio
n
Phase II
(8E)-8-
[hydroxy-[(5-
methyl-1,3-
thiazol-2-
yl)amino]methyl
idene]-9-methyl-
10,10-dioxo-
10 6-thia-9-
azabicyclo[4.4.0
]deca-1,3,5-
trien-7-one
4.51+/
-0.8
micro
M
headach
e,
fatigue
related
to
anemia
Phase III
353
http://%20void%20window.open%28%27../image/structurefly.cgi?cid=5281106&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)http://%20void%20window.open%28%27../image/structurefly.cgi?cid=3308&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)http://%20void%20window.open%28%27../image/structurefly.cgi?cid=5426&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)http://%20void%20window.open%28%27../image/structurefly.cgi?cid=6236&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)http://%20void%20window.open%28%27../image/structurefly.cgi?cid=4495&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)8/7/2019 probir project
36/55
ibuprofen 2-[4-(2-methylpropyl)ph
enyl]propanoic
acid
3.8
+/-0.7
micro
M
ulcerati
ons,
abdomi
nal pain
Phase III
Naproxen sodium (2S)-2-(6-
methoxynaphtha
len-2-
yl)propanoate
3.4
+/-0.4
micro
M
headach
e, and
dizzines
s
Phase II
Table4.4 shows the chemical formula, molecular weight, chemical structure and IUPAC
name of different inhibitors which show interaction with COX2(cyclooxygenase2).
protein. The IUPAC name of the inhibitor is further used in making pdb file of that
inhibitor.
4.5 Docking of ligand to receptor
4.5.1 AUTODOCK RESULTS
Table 4.2: Docked energies and other parameters of the inhibitors using Auto Dock
docking program.
363
http://%20void%20window.open%28%27../image/structurefly.cgi?cid=169117&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)http://%20void%20window.open%28%27../image/structurefly.cgi?cid=3672&width=400&height=400%27,%20%27StructureFly%27,%20%27resizable=yes,%20scrollbars=yes,%20WIDTH=620,%20HEIGHT%20=%20620%27)8/7/2019 probir project
37/55
Table 4.2 shows the results displayed by Autodock docking program displaying Free-energy, Intermolecular-energy, Internal-energy and finally Docked energy of the COX2
(cyclooxygenase2) with its inhibitor. Autodock docking results show that Bellnamine
inhibitor of COX2 (cyclooxygenase2) shows best interaction with the
COX2(cyclooxygenase2), with its docked energy of 19.79.
4.6 Python Molecular Viewer (PMV) Results:
SN Inhibitor
Name
Docked
Energy
Ref
RMS
Free
Energy
Intermolecular
Energy
Internal
Energy1 Etodolac -15.1 37.3 -16.4 -17.67 2.572 Nimesulide -2.01 35.3 -1.73 -2.98 0.96
3 Etoricoxib -15.1 37.3 -16.74 -17.67 2.574 Melocoxib -17.49 55.47 -16.56 -18.12 0.635 Valdecoxib -19.3 31.18 -11.04 -19.13 0.06 Doxorubicin -16.78 24.05 -18.97 -19.9 3.127 Thalidomide -11.84 36.61 -11.22 -11.84 0.08 Ibuprofen -8.87 25.68 -9.49 -10.74 1.879 Naproxene -19.79 32.53 -11.7 -19.79 0.010 Rofecoxib -19.1 28.56 -16.92 -19.1 0.0
373
8/7/2019 probir project
38/55
Fig 4.6.1.: Hydrogen Bond Formed Between Proteins Active Site and Inhibitor
Etorocoxib
383
8/7/2019 probir project
39/55
Fig 4.6.2.: Hydrogen Bond Formed Between Proteins Active Site and Inhibitor Etodolac
393
8/7/2019 probir project
40/55
Fig 4.6.3.: Hydrogen Bond Formed Between Proteins Active Site and Inhibitor Nimesulide
404
8/7/2019 probir project
41/55
Fig4.6.4.: Hydrogen Bond Formed Between proteins Active Site and Inhibitor Doxorubicin
414
8/7/2019 probir project
42/55
Fig4.6.5.: Hydrogen Bond Formed Between Proteins Active Site and Inhibitor
Melocoxib
424
8/7/2019 probir project
43/55
Fig 4.6.6.: Hydrogen Bond Formed Between Proteins Active Site and Inhibitor
Thalidomide
434
8/7/2019 probir project
44/55
Fig 4.6.7.: Hydrogen Bond Formed Between Proteins Active Site and Inhibitor
Rofecoxib
444
8/7/2019 probir project
45/55
Fig 4.6.8.: Representation Of The Interaction between the protein and Valdecoxib
454
8/7/2019 probir project
46/55
Fig 4.6.9.: Representation Of The Interaction between the protein and Ibuprofen
464
8/7/2019 probir project
47/55
Fig 4.6.10.: Representation Of The Interaction between the protein and Naproxene
DISCUSSION
Rational Drug Designing Strategies reduce a lot of time ,money and energy as compared
to other hit and trial methods.According to recent trends mathematical modelling has
become very valuable.The use of sophasticated softwares and tools greatly help in this
process,helping furthur development in research and development in this field. The
474
8/7/2019 probir project
48/55
main concern in AutoDock is computation of docking energy,which essentially should be
less than zero.The more negative the docking energy,the better it is.
Fig 4.7. Shows the relative docked energies of various inhibitors with the target protein.
From the figure we can conclude that Naproxene has the minimum docked
energy,hence the best inhibitor
484
8/7/2019 probir project
49/55
CONCLUSION
After the project work on rational drug design for COX 2,the conclusion is that out of all
the inhibitors chosen for the docking,naproxene emerged to be be the best inhibitor for the protein COX 2.The precise reason for it was its docking energy which was the
lowest(docked energy=-19.79),among all other inhibitors used.Hence the conclusion is
that naproxene is the best inhibitor,for COX 2.Hence the task was completed
successfully.
Cancer is a major threat to the worlds health.There are many reasons and factors
responsible for induction of cancer.COX 2 is also one of those factors responsible for the
induction of cancer.Basically COX 2 is an enzyme present in our body which is anintegral part of the inflamatory responses of our immune system.If due to any reason the
secretion of this enzyme crosses a perticular threshold,it can cause tumor formation.This
tumor may under the influence of mitogens and other carcinogens can cause cancer.The
threat if cancer bein cause by COX 2 has spread globally and many bio-pharma giants
have launched several medicines eg:Celebrex,Vioxx etc.The main concern is to reduce
the over-expression of COX 2 and not to terminate its secretion completely.There are
many inhibitors which are used for the inhibition of over secretion of COX 2.Out of
many inhibitors,some are rejected due to their side effects,as gastric ulcer in case of
aspirin.However there is no inhibihitor which is fully perfect and without any
sideeffects.Nevertheless we try to reduce the burden on the general health of the patient
to the maximum extent possible.Hence ,newer drugs are required which have the same
efficacy as the older one but are having fewer side effects.The intial phase of discovering
a new drug nowadays is by using CADD.This method has greately reduced the time
,energy and money involved in the traditional methods.After a drug has been designined
in-silico,its furthur verification is done,as stated earlier in laoratories.This method of
using computer to design the drugs has indeed hastened the process of drug discovery.
Rational Drug Designing Strategies reduce a lot of time ,money and energy as compared
to other hit and trial methods.According to recent trends mathematical modelling has
494
8/7/2019 probir project
50/55
8/7/2019 probir project
51/55
REFERENCES
Andrew,T.C., Shuji,O., Charles,S.F.,(2005), Aspirin and the Risk of Colorectal Cancer
in Relation to the Expression of COX-2, The New England Journal Of Medicine, 5: 685-
693.
Anna,M., Francesca,M.D., Duccio,R., Arganini,L., Taddei,A. F.,and Mennonna,
(2007), Cyclooxygenase-2 (COX-2) Overexpression in Meningiomas: Real Time PCR
and Immunohistochemistry, Applied Immunohistochemistry & Molecular Morphology ,
15: 187-192.
Barbara,W., Kuzbicki, and Lukasz, (2007), Cyclooxygenase-2 (COX-2): first
immunohistochemical marker distinguishing early cutaneous melanomas from benign
melanocytic skin tumours, Melanoma Research , 17: 139-145.
Jana,P., Samia,S., Stuart,A.G., Susan,E., and Kathryn,C.,A(2002), cyclooxygenase-2(COX-2) inhibitor compared with dexamethasone in a survival study of rats with
intracerebral 9L gliosarcomas, Nuero Oncology , 4: 22-25.
Jeroen,H., Elise S.V.H., Robert,V.,Thomas,A., and Maximal (2005), COX-2 and
ppRb expression in neurons occurs during early Braak stages prior to the maximal
activation of astrocytes and microglia in Alzheimer's disease, Journal of
Neuroinflammation , 2: 27-28.
Lisa,A.T., Mark,G.P., and Nicolas,G.B.,(2002), Post-Training Cyclooxygenase-2
(COX-2) Inhibition Impairs Memory Consolidation, Learning Memory ,. 9: 41-47.
515
8/7/2019 probir project
52/55
Marco,L., Sonia,V., Andreas,T., and Maria,D.,(2005), Cyclooxygenase-2 (COX-2) is
frequently expressed in multiple myeloma and is an independent predictor of poor
outcome,Blood, 6: 880-888 .
Phuong,O.T.T., Catherine,E.G., and Robertson,P.R.,(2002), Inhibition of Interleukin-
1-Induced COX-2 and EP3 Gene Expression by Sodium Salicylate Enhances Pancreatic
Islet -Cell Function, Diabetes, 51: 112-118.
Robert,S.B., Michael,L., and Ross P., (2005), Cardiovascular events associated with
rofecoxib in a colorectal adenoma chemoprevention trial, New England Journal of
Medicine, , 11: 1092-1102.
Commonly used websites:
www.ncbi.nlm.nih.gov/
www.pdb.org
http://redpoll.pharmacy.ualbarta.ca/drugbank. http//:Swissmodel.expasy.org/workspace
Journals:
Applied Immunochemistry And Molecular Morphology.
Blood
Cancer Biology
Diabetes
Health Affairs
Journal Of Neuroinfllammation.
Learning Memory
Melanoma Research
525
8/7/2019 probir project
53/55
Nuero Oncology
The New England Journal of Medicine
Neuro Oncology
The New England Journal Of Medicine
Thieme Docking
Abbreviations:
NCBI-National Center Of Biotechnology Information.
COX-Cyclooxygenase.
PDB-Protein Data Bank.
BLAST-Basic Local Alignment Search Tool.CADD-Computer Aided Drug Designing.
535
8/7/2019 probir project
54/55
.
545
8/7/2019 probir project
55/55